Prelude Therapeutics’ (PRLD) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reissued their buy rating on shares of Prelude Therapeutics (NASDAQ:PRLD – Free Report) in a research note published on Monday morning,Benzinga reports. The firm currently has a $5.00 price target on the stock. Separately, JMP Securities restated a “market outperform” rating and set a $4.00 price target on shares of Prelude Therapeutics in […]
HC Wainwright reissued their buy rating on shares of Prelude Therapeutics (NASDAQ:PRLD – Free Report) in a research note published on Monday morning,Benzinga reports. The firm currently has a $5.00 price target on the stock. Separately, JMP Securities restated a “market outperform” rating and set a $4.00 price target on shares of Prelude Therapeutics in […]
